Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure - A report from the Vesnarinone Trial
Autore:
Deswal, A; Petersen, NJ; Feldman, AM; White, BG; Mann, DL;
Indirizzi:
Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect, Houston,TX 77030 USA Vet Affairs Med Ctr Houston TX USA 77030 rdiol Sect, Houston,TX 77030 USA Baylor Coll Med, Dept Med, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Med, Dept Med, Houston, TX 77030 USA Baylor Coll Med, Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 tr Excellence, Houston, TX 77030 USA Univ Pittsburgh, Cardiovasc Inst, Med Hlth Syst, Pittsburgh, PA 15260 USA Univ Pittsburgh Pittsburgh PA USA 15260 th Syst, Pittsburgh, PA 15260 USA
Titolo Testata:
CHEST
fascicolo: 2, volume: 120, anno: 2001,
pagine: 453 - 459
SICI:
0012-3692(200108)120:2<453:EOVOPC>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; POSITIVE INOTROPIC AGENT; FACTOR-ALPHA; CARDIOTONIC AGENT; MONONUCLEAR-CELLS; OPC-8212; BLOOD; PENTOXIFYLLINE; AMIODARONE;
Keywords:
cytokine; heart failure; interleukin-6; receptor; soluble interleukin-6 receptor; soluble tumor necrosis factor-receptor type 1; soluble tumor necrosis factor-receptor type 2; tumor necrosis factor-alpha; vesnarinone;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Mann, DL Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Cardiol Sect,2002 Holcombe Blvd, Houston, TX 77030 USA Vet Affairs Med Ctr 2002 Holcombe Blvd Houston TX USA 77030 0 USA
Citazione:
A. Deswal et al., "Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure - A report from the Vesnarinone Trial", CHEST, 120(2), 2001, pp. 453-459

Abstract

Study objectives: Proinflammatory cytokines may contribute to disease progression in heart failure by virtue of the direct toxic effects that these molecules exert on the heart and the circulation. that Accordingly, there isinterest in developing therapeutic agents with anticytokine properties that might be used as adjunctive therapy to modulate proinflammatory cytokine levels in patients with o`W,heart failure. Previous experimental studies suggested that vesnarinone has potent anticytokine properties in vitro. Therefore, we examined the effects of vesnarinone on circulating levels of cytokines and cytokine receptors in a large-scale, multicenter, clinical trial of patients with moderate-to-advanced heart failure: the Vesnarinone Trial (VEST). Methods: Circulating levels of tumor necrosis factor (TNF)-alpha, soluble TNF-receptor type 1, soluble TNF-receptor type 2, as well as interleukin (IL)-6 and soluble IL-6 receptor (sIL-6R) were measured on plasma samples by enzyme-link-ed immunosorbent assay at baseline and at 24 weeks in patients who were receiving placebo (n = 352), 30 mg of vesnarinone (n = 367), and 60 mg of vesnarinone (n = 327). Results: Treatment with 30 mg and 60 mg of vesnarinone had no effect on circulating levels of cytokines or cytokine receptors in patients with advanced heart failure over a 24-week period. Conclusions: In contrast to the potent anticytokine effects observed with vesnarinone in experimental studies in vitro, the results of this clinical study suggest that vesnarinone does not have any measurable anticytokine effects in vivo in patients with moderate-to-advanced heart failure.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 15:14:54